ImCheck Therapeutics

ImCheck Therapeutics

Biotechnologie

Marseille, Provence-Alpes-Cote d'Azur 9 205 abonnés

Bringing a novel class of Butyrophilin-targeted checkpoint modulators into the clinic

À propos

ImCheck Therapeutics is designing and developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel super-family of immunomodulators. As demonstrated by lead clinical-stage program ICT01, which has a mechanism of action to simultaneously modulate innate and adaptive immunity, ImCheck's “first-in-class” activating antibodies may be able to produce superior clinical results as compared to the first-generation of immune checkpoint inhibitors and, when used in combination, to overcome resistance to this group of agents. In addition, ImCheck’s antagonist antibodies are being evaluated as potential treatments for a range of autoimmune diseases. Co-founder of the Marseille Immunopole cluster, ImCheck benefits from support from Prof. Daniel Olive (INSERM, CNRS, Institut Paoli Calmettes, Aix-Marseille Université), a worldwide leader in γδ T cells and butyrophilins research; from the experience of an expert management team; and from the commitment of leading US and European investors.

Secteur
Biotechnologie
Taille de l’entreprise
11-50 employés
Siège social
Marseille, Provence-Alpes-Cote d'Azur
Type
Société civile/Société commerciale/Autres types de sociétés
Fondée en
2015
Domaines
antibodies, immuno-oncology, Immune checkpoint Modulators, Auto-immunity, innate immunity, oncology, cancer, precision-based medicine, adaptative immunity, EVICTIONtrial, ICT01 et gamma-deltaTcells

Lieux

Employés chez ImCheck Therapeutics

Nouvelles

Pages similaires

Parcourir les offres d’emploi

Financement

ImCheck Therapeutics 7 rounds en tout

Dernier round

Subside

22 470 759,00 $US

Investisseurs

France 2030
Voir plus d’informations sur Crunchbase